AC Immune Reports Positive Phase 1 ALS Imaging Data for ACI-19626
LAUSANNE, Switzerland, May 22, 2026 AC Immune announced new preliminary Phase 1 data showing that its investigational TDP-43 PET...
Neurodegenerative Diseases
Advertisement
FDA Expands Drug Repurposing Initiative for Rare Diseases
WASHINGTON, May 11, 2026 The U.S. Food and Drug Administration announced a new initiative aimed at accelerating drug repurposing...
AC Immune Advances ACI-24 Alzheimer’s Trial Expansion
LAUSANNE, Switzerland, April 2026 AC Immune SA announced continued progress in its Phase 1b/2 ABATE clinical trial evaluating ACI-24,...
Alamar Launches Neuro 220 Panel for Precision Proteomics
Fremont, California, March 17, 2026 Alamar Biosciences, Inc. announced the launch of its NULISAseq™ Neuro 220 Panel, a next-generation...
Tau Immunotherapy AADvac1 Enters Landmark AD Trial
SAN FRANCISCO, Calif., Feb. 4, 2026 — Axon Neuroscience announced that its active tau immunotherapy AADvac1 has been selected...
Advertisements
VectorY and ShapeTX Partner to Advance AAV5-Based CNS Therapies
AMSTERDAM, BOSTON, and SEATTLE – Sept. 18, 2025 (cGxP.wire) – VectorY Therapeutics, a biotechnology company pioneering vectorized antibody therapies...
Advertisement
